# 1. Financial Performance ## A. Key Figures * **9M Revenue from Operations:** ₹2,702 Cr (+3%) · **Q3 Revenue from Operations:** ₹917 Cr (–3%) * **Q3 EBITDA:** ₹225 Cr (–26%) · **EBITDA Margin:** 24% (–700 bps) * **Q3 PAT (before exceptional items):** ₹73 Cr (–44%) · **PAT Margin:** 8% (–600 bps) * **9M EBITDA:** ₹664 Cr (–12%) · **EBITDA Margin:** 24% (–400 bps) * **9M PAT (before exceptional items):** ₹227 Cr (–22%) · **PAT Margin:** 8% (–300 bps) ## B. Revenue Trends * **Mixed Top-Line Performance:** Nine-month revenue showed modest growth, but Q3 declined **3% YoY**, with flat QoQ performance signaling stabilization amid client-specific headwinds. * **Operational Revenue Pressures:** Revenue from operations down **(8)% in Q3**, while reported revenue fell only **(1)%** due to lower other income, indicating core business softness. * **Cost Structure Deterioration:** Despite a slight improvement in material costs, **staff costs rose 4% YoY** and expanded as a percentage of revenue by **337 bps**, reflecting wage inflation and structural cost pressures. ## C. Profit Margins * **Sharp Margin Contraction:** EBITDA and PAT margins declined significantly in Q3, driven by **rising staff and other direct costs**, even as material cost efficiency improved. * **Exceptional Drag on Profits:** A **₹579 Mn loss** from an insurance claim settlement (2016 fire incident) was recorded as an exceptional item, sharply reducing PAT after exceptional items to **₹150 Mn in Q3**. * **Sustained Cost Inflation:** Staff cost ratio increased by **276 bps** over 9M, while other expenses rose **4%** and their margin share expanded, pressuring operating leverage. ## D. Balance Sheet * **Capex Cycle Progressing:** PPE increased to **₹25,501 Mn** from **₹23,226 Mn**, while capital work-in-progress declined from **₹12,614 Mn to ₹10,311 Mn**, indicating recent project completions. * **Liquidity Tightened:** Cash and cash equivalents dropped from **₹3,671 Mn to ₹1,940 Mn**, and total current assets fell to **₹19,498 Mn** from **₹22,873 Mn**, though balance sheet remains debt-light and strong. * **Tax Assets Surged:** Deferred tax assets (net) more than doubled to **₹821 Mn** from **₹295 Mn**, and income tax assets rose to **₹1,559 Mn**, suggesting future tax benefits. ## E. Cash Flow * **FX Volatility Impact:** Net foreign exchange fluctuation turned into a **loss of ₹233 Mn in Q3**, reversing prior gains and negatively impacting cash flow from operations. * **Improved 9M FX Position:** Over nine months, FX swung from a **loss of ₹399 Mn** to a **gain of ₹26 Mn**, providing a partial offset to quarterly volatility. --- # 2. Segment & Service Growth ## A. Research Services * **Headline:** Research Services demonstrates steady growth, with new program wins signaling strong client demand and business momentum. ## B. Integrated Offerings * **Headline:** Performance decline attributed to ongoing disruption from **a single large-molecule biologics client's product-related issue**, indicating a concentrated, non-systemic challenge. --- # 3. Capacity & Capex ## A. Key Figures * Capex (CWP): ₹2,981 Mn biologics site acquisition (USD 34.89 Mn) ## B. New Facilities * **OSD Platform Enhanced:** Commissioning of a new commercial-scale facility for liquid-filled hard gelatin capsules strengthens oral solid dosage capabilities, enabling development of **complex, hard-to-dissolve medicines**. ## C. Chemistry Expansion * **Advanced Chemistry Scaling:** Expansion of catalytic screening and flow chemistry labs in Hyderabad enables parallel reaction testing and **faster synthesis turnaround**, boosting efficiency and scalability in drug substance delivery. ## D. Biologics Investment * **Strategic U.S. Entry:** Acquisition of a U.S.-based biologics site adds **50,000L single-use bioreactor capacity**, marking a major step in global footprint expansion. * **Bangalore Facility Ramped:** Regulatory clearance in FY25 Q2 enabled capitalization of assets and commencement of operations, with depreciation impact now reflected in results. --- # 4. Client & Partnership ## A. Strategic Partnership Expansion * **Long-Term BMS Alliance:** Syngene secured a strategic ten-year extension of its collaboration with **Bristol Myers Squibb (BMS) through 2035**, reinforcing a cornerstone client relationship. * **Expanded Service Scope:** Partnership now covers **integrated drug development services** across discovery, translational sciences, pharmaceutical development and manufacturing, and clinical trials. ## B. Global Client & Operational Reach * **Diversified Global Base:** Serves **400 global customers**, including leading biotechs and multinationals such as **BMS, GSK, Zoetis, and Merck KGaA**, underscoring broad market trust. * **International Footprint:** Operates research and manufacturing facilities in **India and the U.S.**, enabling global service delivery and client proximity. --- # 5. Regulatory & Labor Risks ## A. Key Figures * **One-Time Gratuity Impact (net of tax):** **₹58 Cr** excluded from Q3 FY26 results * Receivables Write-Off (pre-tax): ₹277 Mn in FY25 Q3 due to FX fluctuations ## B. Labour Code Impact * **Regulatory Shift:** New Labour Codes consolidate **29 legacy laws**, introducing material financial impacts including a one-time charge from increased gratuity liabilities. * **Accounting Volatility:** Exceptional items swung from a significant gain to a charge, contributing to a **1% decline** in key financial metrics. * **Ongoing Uncertainty:** Group is actively assessing draft Central Rules and FAQs; final compliance actions and accounting treatments await government clarifications. ## C. Compliance Monitoring * **Operational Excellence Recognition:** Syngene’s T&CR unit achieved **5S Certification** from JUSE and QCFI, a first among Indian pharma/biotech firms. --- # 6. Guidance & Outlook ## A. Recognition & Market Position * **Top Global Ranking:** Syngene ranked among the **'World's Best Companies in Sustainable Growth 2026'** by TIME and Statista, placing in the **global top three** and **#1 in India** in Pharma & Biotech—its second major recognition in six months.